{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:17:42Z","timestamp":1792516662303,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-59744-9","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T03:54:47Z","timestamp":1747367687000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1164-3779","authenticated-orcid":false,"given":"Oscar","family":"Arrieta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Lara-Mej\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2422-1671","authenticated-orcid":false,"given":"Eduardo","family":"Rios-Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Caball\u00e9-Perez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Cabrera-Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maritza","family":"Ramos-Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"D\u00e1vila-Dupont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s F.","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graciela","family":"Cruz-Rico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9462-875X","authenticated-orcid":false,"given":"Jordi","family":"Remon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Garcilazo-Reyes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Rosell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"59744_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000493733","volume":"96","author":"O Arrieta","year":"2019","unstructured":"Arrieta, O. et al. Molecular epidemiology of ALK rearrangements in advanced lung adenocarcinoma in Latin America. Oncology 96, 207\u2013216 (2019).","journal-title":"Oncology"},{"key":"59744_CR2","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1038\/s43018-023-00515-0","volume":"4","author":"JL Schneider","year":"2023","unstructured":"Schneider, J. L., Lin, J. J. & Shaw, A. T. ALK-positive lung cancer: a moving target. Nat. Cancer 4, 330\u2013343 (2023).","journal-title":"Nat. Cancer"},{"key":"59744_CR3","doi-asserted-by":"publisher","first-page":"iii4","DOI":"10.1093\/annonc\/mdw301","volume":"27","author":"B Hallberg","year":"2016","unstructured":"Hallberg, B. & Palmer, R. H. The role of the ALK receptor in cancer biology. Ann. Oncol. 27, iii4\u2013iii15 (2016).","journal-title":"Ann. Oncol."},{"key":"59744_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters, S. et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N. Engl. J. Med. 377, 829\u2013838 (2017).","journal-title":"N. Engl. J. Med."},{"key":"59744_CR5","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","volume":"6","author":"JF Gainor","year":"2016","unstructured":"Gainor, J. F. et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 6, 1118\u20131133 (2016).","journal-title":"Cancer Discov."},{"key":"59744_CR6","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1517\/14728222.2010.511617","volume":"14","author":"AL Jackson","year":"2010","unstructured":"Jackson, A. L., Zhou, B. & Kim, W. Y. HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer. Expert Opin. Ther. Targets 14, 1047\u20131057 (2010).","journal-title":"Expert Opin. Ther. Targets"},{"key":"59744_CR7","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/JTO.0000000000000366","volume":"10","author":"RG Zinner","year":"2015","unstructured":"Zinner, R. G. et al. PRONOUNCE: randomized, open-label, phase III study of first-line pemetrexed + carboplatin followed by maintenance pemetrexed versus paclitaxel + carboplatin + bevacizumab followed by maintenance bevacizumab in patients ith advanced nonsquamous non-small-cell lung cancer. J. Thorac. Oncol. 10, 134\u2013142 (2015).","journal-title":"J. Thorac. Oncol."},{"key":"59744_CR8","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1016\/S1470-2045(19)30634-5","volume":"20","author":"K Nakagawa","year":"2019","unstructured":"Nakagawa, K. et al. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20, 1655\u20131669 (2019).","journal-title":"Lancet Oncol."},{"key":"59744_CR9","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s43018-021-00195-8","volume":"2","author":"A Passaro","year":"2021","unstructured":"Passaro, A., Janne, P. A., Mok, T. & Peters, S. Overcoming therapy resistance in EGFR-mutant lung cancer. Nat. Cancer 2, 377\u2013391 (2021).","journal-title":"Nat. Cancer"},{"key":"59744_CR10","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1016\/j.jtho.2022.05.008","volume":"17","author":"MC Piccirillo","year":"2022","unstructured":"Piccirillo, M. C. et al. Addition of bevacizumab to erlotinib as first-line treatment of patients With EGFR-mutated advanced nonsquamous NSCLC: the BEVERLY multicenter randomized phase 3 trial. J. Thorac. Oncol. 17, 1086\u20131097 (2022).","journal-title":"J. Thorac. Oncol."},{"key":"59744_CR11","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.cllc.2023.02.010","volume":"24","author":"M Nishio","year":"2023","unstructured":"Nishio, M. et al. RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in untreated metastatic EGFR-mutant NSCLC (EGFR+ NSCLC): association between TP53 status and clinical outcome. Clin. Lung Cancer 24, 415\u2013428 (2023).","journal-title":"Clin. Lung Cancer"},{"key":"59744_CR12","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1038\/nm.3930","volume":"21","author":"G Hrustanovic","year":"2015","unstructured":"Hrustanovic, G. et al. RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer. Nat. Med. 21, 1038\u20131047 (2015).","journal-title":"Nat. Med."},{"key":"59744_CR13","doi-asserted-by":"publisher","first-page":"6094","DOI":"10.1158\/0008-5472.CAN-14-0268","volume":"74","author":"C Martinengo","year":"2014","unstructured":"Martinengo, C. et al. ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis. Cancer Res. 74, 6094\u20136106 (2014).","journal-title":"Cancer Res."},{"key":"59744_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100342","volume":"7","author":"JJ Lin","year":"2022","unstructured":"Lin, J. J. et al. Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I\/II study. ESMO Open 7, 100342 (2022).","journal-title":"ESMO Open"},{"key":"59744_CR15","doi-asserted-by":"publisher","first-page":"9074","DOI":"10.1200\/JCO.2022.40.16_suppl.9074","volume":"40","author":"O Arrieta","year":"2022","unstructured":"Arrieta, O. et al. A phase II study of alectinib in combination with bevacizumab as first-line treatment in advanced NSCLC with confirmed ALK fusion: ALEK-B trial. J. Clin. Oncol. 40, 9074\u20139074 (2022).","journal-title":"J. Clin. Oncol."},{"key":"59744_CR16","doi-asserted-by":"publisher","first-page":"3592","DOI":"10.1200\/JCO.20.00505","volume":"38","author":"DR Camidge","year":"2020","unstructured":"Camidge, D. R. et al. Brigatinib versus crizotinib in advanced ALK inhibitor-naive ALK-positive non-small cell lung cancer: second interim analysis of the phase III ALTA-1L trial. J. Clin. Oncol. 38, 3592\u20133603 (2020).","journal-title":"J. Clin. Oncol."},{"key":"59744_CR17","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1016\/S2213-2600(22)00437-4","volume":"11","author":"BJ Solomon","year":"2023","unstructured":"Solomon, B. J. et al. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study. Lancet Respir. Med. 11, 354\u2013366 (2023).","journal-title":"Lancet Respir. Med."},{"key":"59744_CR18","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw, A. T. et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. N. Engl. J. Med 383, 2018\u20132029 (2020).","journal-title":"N. Engl. J. Med"},{"key":"59744_CR19","doi-asserted-by":"crossref","unstructured":"Solomon B. J., et al. Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the phase III CROWN study. J. Clin. Oncol. 42, 3400\u20133409 (2024).","DOI":"10.1200\/JCO.24.00581"},{"key":"59744_CR20","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1016\/j.annonc.2020.04.478","volume":"31","author":"T Mok","year":"2020","unstructured":"Mok, T. et al. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study. Ann. Oncol. 31, 1056\u20131064 (2020).","journal-title":"Ann. Oncol."},{"key":"59744_CR21","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1093\/annonc\/mdy405","volume":"29","author":"S Gadgeel","year":"2018","unstructured":"Gadgeel, S. et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann. Oncol. 29, 2214\u20132222 (2018).","journal-title":"Ann. Oncol."},{"key":"59744_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jtho.2023.08.007","volume":"19","author":"L Lara-Mejia","year":"2023","unstructured":"Lara-Mejia, L. et al. Impact of concurrent genomic alterations on clinical outcomes in patients with ALK-rearranged NSCLC. J. Thorac. Oncol. 19, 119\u2013129 (2023).","journal-title":"J. Thorac. Oncol."},{"key":"59744_CR23","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1200\/JCO.2015.62.0138","volume":"34","author":"KL Johung","year":"2016","unstructured":"Johung, K. L. et al. Extended survival and prognostic factors for patients with ALK-rearranged non-small-cell lung cancer and brain metastasis. J. Clin. Oncol. 34, 123\u2013129 (2016).","journal-title":"J. Clin. Oncol."},{"key":"59744_CR24","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1200\/JCO.21.02278","volume":"40","author":"BJ Solomon","year":"2022","unstructured":"Solomon, B. J. et al. Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the phase III CROWN study. J. Clin. Oncol. 40, 3593\u20133602 (2022).","journal-title":"J. Clin. Oncol."},{"key":"59744_CR25","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","volume":"16","author":"DR Camidge","year":"2021","unstructured":"Camidge, D. R. et al. Brigatinib versus crizotinib in ALK inhibitor-naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial. J. Thorac. Oncol. 16, 2091\u20132108 (2021).","journal-title":"J. Thorac. Oncol."},{"key":"59744_CR26","doi-asserted-by":"crossref","unstructured":"Parikh, K. et al. Impact of EML4-ALK variants and co-occurring TP53 mutations on duration of first-line ALK tyrosine kinase inhibitor treatment and overall survival in ALK fusion-positive NSCLC: real-world outcomes from the GuardantINFORM database. J. Thorac. Oncol. 19, 1539\u20131549 (2024).","DOI":"10.1016\/j.jtho.2024.07.009"},{"key":"59744_CR27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.3390\/cancers15010204","volume":"15","author":"S Watanabe","year":"2022","unstructured":"Watanabe, S. et al. Phase II trial of the combination of alectinib with bevacizumab in alectinib refractory ALK-positive nonsquamous non-small-cell lung cancer (NLCTG1501). Cancers 15, 204 (2022).","journal-title":"Cancers"},{"key":"59744_CR28","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","volume":"49","author":"X Zhu","year":"2007","unstructured":"Zhu, X., Wu, S., Dahut, W. L. & Parikh, C. R. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am. J. Kidney Dis. 49, 186\u2013193 (2007).","journal-title":"Am. J. Kidney Dis."},{"key":"59744_CR29","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S1470-2045(10)70151-0","volume":"11","author":"L Crino","year":"2010","unstructured":"Crino, L. et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol. 11, 733\u2013740 (2010).","journal-title":"Lancet Oncol."},{"key":"59744_CR30","doi-asserted-by":"publisher","first-page":"10556","DOI":"10.3390\/ijms231810556","volume":"23","author":"D Frankel","year":"2022","unstructured":"Frankel, D. et al. Comparison between immunocytochemistry, FISH and NGS for ALK and ROS1 rearrangement detection in cytological samples. Int. J. Mol. Sci. 23, 10556 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"59744_CR31","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.lungcan.2022.11.004","volume":"174","author":"J Mazieres","year":"2022","unstructured":"Mazieres, J. et al. Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer. Lung Cancer 174, 146\u2013156 (2022).","journal-title":"Lung Cancer"},{"key":"59744_CR32","doi-asserted-by":"publisher","first-page":"TPS9144","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9144","volume":"40","author":"M Duruisseaux","year":"2022","unstructured":"Duruisseaux, M. et al. A phase II randomized, open-labelled, multicenter study of safety and efficacy of combination brigatinib and carboplatin-pemetrexed therapy or brigatinib monotherapy as first-line treatment in patients with advanced ALK-positive non\u2013small cell lung cancer (IFCT-2101 MASTERPROTOCOL ALK). J. Clin. Oncol. 40, TPS9144\u2013TPS9144 (2022).","journal-title":"J. Clin. Oncol."},{"key":"59744_CR33","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228\u2013247 (2009).","journal-title":"Eur. J. Cancer"},{"key":"59744_CR34","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.lungcan.2019.10.002","volume":"138","author":"M Perol","year":"2019","unstructured":"Perol, M. et al. Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer. Lung Cancer 138, 79\u201387 (2019).","journal-title":"Lung Cancer"},{"key":"59744_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","volume":"10","author":"R Simon","year":"1989","unstructured":"Simon, R. Optimal two-stage designs for phase II clinical trials. Control Clin. Trials 10, 1\u201310 (1989).","journal-title":"Control Clin. Trials"}],"updated-by":[{"DOI":"10.1038\/s41467-025-67648-x","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59744-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59744-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59744-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T06:29:44Z","timestamp":1765607384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-59744-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["59744"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-59744-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"29 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41467-025-67648-x","URL":"https:\/\/doi.org\/10.1038\/s41467-025-67648-x","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.A. reports personal fees from Pfizer, Lilly, Merck, and Bristol Myers Squibb, and grants and personal fees from Astra Zeneca, Boehringer Ingelheim, and Roche. L.L.-M. has participated as a speaker for Astra Zeneca, Roche, Pfizer, Takeda, Janssen Cilag and Boehringer Ingelheim and personal fees from Janssen Cilag, Pfizer, Takeda, and Roche. A.F.C.: reports grants from Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb and The Foundation for Clinical and Applied Cancer Research\u2014FICMAC., other from Pfizer, Boehringer Ingelheim, Astra Zeneca, MSD, BMS, Celldex, Roche, personal fees from Merck Sharp & Dohme, Boehringer Ingelheim, Roche, Bristol-Myers Squibb, Pfizer, Novartis, Celldex Therapeutics, Foundation Medicine, Eli Lilly and Foundation for Clinical and Applied Cancer Research\u2014FICMAC, outside the submitted work. The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4553"}}